Genezen receives growth equity investment from Ampersand Capital Partners

Scroll Down

Genezen, Inc., a cell and gene therapy Contract Development and Manufacturing Organization (CDMO) focused on early-phase process development, vector production, and analytical testing services, today announced a majority investment from Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the healthcare sector. Ampersand’s investment will be used to complete the construction of the company’s 25,000 square foot cGMP-compliant lentiviral vector production facility, which will also offer a full suite of process development and analytical capabilities.

Read the full press release here.

You may also be interested in...

Genezen Appoints New CEO as GMP…

Genezen Inc., a cell and gene therapy Contract Development and Manufacturing...

Read more

A time of flux: opportunities and…

In this blog, Katherine Moynihan, VP of Business Development and Marketing...

Read more

Meeting Demand for Biologics

With the recent tendency of drug developers to outsource their formulation...

Read more

Balancing Biopharma’s Pressing Priorities

With intense pressure continuing to be placed upon the pharmaceutical industry...

Read more